arrow
A

Amelia Filippelli

University of Salerno
H指数:43
被引数:5,922

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Need for Medication Review and Deprescribing in People Living with HIV: A Longitudinal Observational Study

HIV感染者药物重审和去处方化的必要性:一项纵向观察性研究

2026-09-020
OA
RAS Inhibitors: Changing the Paradigm from the Undruggable

RAS抑制剂:改变不可成药靶点的范式

2026-07-280
OA
Sex differences in levodopa pharmacokinetics in early Parkinson’s disease: implications on levodopa-related complications

早期帕金森病中左旋多巴药代动力学的性别差异:对左旋多巴相关并发症的影响

2026-04-070
OAAI
Pharmacogenetic testing in Italy: results of a nationwide survey by the Joint Working Group for the pharmacogenetics implementation in Italy

意大利的药物基因组学检测:意大利药物基因组学实施联合工作组开展的一项全国性调查结果

2026-04-030
OAAI
Sex differences among elderly ACS patients undergoing percutaneous coronary intervention receiving Ticagrelor 60 mg vs. 90 mg

老年ACS患者接受经皮冠状动脉介入治疗时,Ticagrelor 60 mg与90 mg的性别差异

2025-11-010
OA
Sex, Age, and Previous Herpes Zoster Infection Role on Adverse Events Following Immunization with Adjuvanted Recombinant Vaccine
2025-02-150
OAAI
Pre- and Post-COVID-19 Antibiotic Consumption and Stewardship Program in a Southern Italian Hospital

意大利南部一家医院的Post-COVID-19抗生素消费和管理计划

2024-11-240
OA
Exploring programmed death cell-1 (PD-1) single nucleotide polymorphisms (SNP) as predictive biomarkers for immune-related adverse events (irAEs) in advanced cancer patients treated with immune checkpoint inhibitors (ICIs)

探索程序性死亡细胞-1 (PD-1) 单核苷酸多态性 (SNP) 作为接受免疫检查点抑制剂 (ICIs) 治疗的晚期癌症患者免疫相关不良事件 (irAEs) 的预测生物标志物

2024-09-010
PRE
Ticagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial
2024-07-181
PRE
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

rs822336与C/ebp β 和NFIC的结合调节PD-L1表达的诱导并预测晚期NSCLC的anti-PD-1/PD-L1治疗

2024-03-257
OAAI
rs822336 as a predictive biomarker for anti-PD-1/PD-L1 immunotherapy in advanced NSCLC: Unraveling molecular mechanisms

rs822336作为晚期NSCLC anti-PD-1/PD-L1免疫治疗的预测性生物标志物: 分子机制

2024-03-220
PRE